Funding Opportunity PAR-24-035 from the NIH Guide for Grants and Contracts. Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)

Funding Opportunity RFA-HG-23-033 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups. The intended FOA will be based on a concept recently approved by the National Advisory Council on Human Genome Research and accompanying discussion. This Notice is being provided to allow potential applicants sufficient time to responsive projects. Details of the planned FOA are provided below.

Funding Opportunity PAR-24-053 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. These research projects will be part of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, which will also include a Coordinating Center (NOFO xxx). Funded under a cooperative agreement, projects participating in the MSPI Research Network will collaborate to share approaches, methods, and data, working closely with NIH Institutes, Offices and Centers. Applicants applying to this NOFO are encouraged to review the Coordinating Center NOFO to fully understand the MSPI Research Network structure and activities. This NOFO solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.

Funding Opportunity PAR-24-036 from the NIH Guide for Grants and Contracts. Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

Funding Opportunity RFA-HG-23-032 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups.

Competitive: CK Group: CK Group are exclusively working with a global biopharmaceutical company and recruiting for an experienced Senior Cheminformatician. The successful candidate will be part of a... Cambridge

Lead, coordinate, and manage the implementation of human research design, setup, data collection, and analysis. 13 paid holidays (staff holiday calendar).
From West Virginia University - Sun, 05 Nov 2023 10:05:37 GMT - View all Morgantown, WV jobs

Lead, coordinate, and manage the implementation of human research design, setup, data collection, and analysis. 13 paid holidays (staff holiday calendar).
From West Virginia University - Sun, 05 Nov 2023 10:05:37 GMT - View all Morgantown, WV jobs

Experience with standard laboratory techniques such as tissue culture, western blotting, immunoprecipitation, extraction and analysis of DNA and RNA, PCR, and… $67,728 - $99,236 a year
From Fred Hutchinson Cancer Center - Sat, 04 Nov 2023 08:59:13 GMT - View all Seattle, WA jobs

F. Hoffmann-La Roche AG: Roche Diagnostics is a cutting-edge biotechnology company dedicated to advancing the field of genomics and diagnostics. We are at the forefront of ... Mississauga, Ontario, Canada

F. Hoffmann-La Roche AG: Roche Diagnostics is a cutting-edge biotechnology company dedicated to advancing the field of genomics and diagnostics. We are at the forefront of ... Mississauga, Ontario, Canada

Funding Opportunity PAR-23-282 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities

Funding Opportunity PAR-24-049 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

Notice NOT-OD-24-025 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-006 from the NIH Guide for Grants and Contracts

St. Jude Children's Research Hospital: We are seeking a talented, highly motivated Senior Bioinformatics Research Scientist to lead our bioinformatics pipeline and develop innovative sol... Memphis, Tennessee

F. Hoffmann-La Roche AG: Principal Bioinformatics Scientist We are seeking a highly skilled and experienced Principal Bioinformatics Scientist specializing in Next Generati... Santa Clara, California, United States of America

Notice NOT-OD-24-018 from the NIH Guide for Grants and Contracts

Notice NOT-PM-24-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-028 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications for one or more Data Coordinating Centers (DCCs) to support BRAIN CONNECTS, a networked consortium of Comprehensive Centers and Specialized Projects funded under RFA-NS-22-047, RFA-NS-22-048, and RFA-NS-22-049. The goals of these awards are to develop the research capacity and technical capabilities for comprehensive brain-wide connectivity mapping in mouse, human, and non-human primate (NHP). BRAIN CONNECTS projects will collect and process unprecedented volumes of anatomical data by scaling up cutting-edge acquisition modalities and analysis methods, to demonstrate the feasibility of collecting, reconstructing, analyzing, integrating, disseminating, and interpreting connectivity maps from entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. NIH expects to fund one or more BRAIN CONNECTS DCCs, which will collaborate with CONNECTS data generating projects to (1) coordinate activities of the BRAIN CONNECTS Network, (2) develop and harmonize common data processing pipelines, (3) integrate and disseminate data analytic tools and capabilities, (4) establish a unified knowledge base for connectivity data of diverse modalities, and (5) organize and implement outreach and engagement to the wider research community and the general public. Awards will be integrated into the BRAIN CONNECTS Network as a coordinated effort aimed at developing the ability to generate wiring diagrams spanning entire brains across multiple scales and species.